Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
The U.K. prime minister prepares to meet his German and French counterparts this week.Europe Politicsread more
Amazon is raising seller fees for thousands of small and medium-sized businesses in France because of a new digital tax passed by the French government.Technologyread more
U.S. stock index futures point to a higher open on Monday morning as the White House sought to calm investors over growing concerns about the U.S. economy.US Marketsread more
Ahead of the deadline, U.S. President Donald Trump told reporters that Huawei was a national security threat.Technologyread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Baidu is gearing up to release its second-quarter earnings on Monday with the market expecting a sharp decline in profit.Technologyread more
Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Stocks in Asia rose on Monday as U.S. Treasury yields bounced higher after plunging last week.Asia Marketsread more
The problem with tanking equities lies elsewhere, writes Michael Ivanovitch, because traders see no end to America's unfolding trade disputes with Europe and China.World Economyread more
Beijing wants to use reforms to support a slowing economy.China Marketsread more
Are you're concerned that the global economy isn't quite as perky as it had been? Cramer is, too.
"That's why I've been highlighting biotech stocks so often lately. They're not cyclical; they typically do equally well regardless of how the economy's doing, " Cramer said.
It's these so-called secular growers that Cramer wants individual investors to consider in the days ahead. And of all the stocks in the space, Cramer said that Isis Pharmaceutical is among his favorites, largely due to the many groundbreaking drugs in its pipeline.
"This company has pioneered what's known as antisense technology, medical speak for drugs that work by binding to the RNA in a person's cells," Cramer said. Already, the company has an effective treatment on the market for a rare disease that causes high cholesterol.
However, that may only be the tip of the iceberg. Currently Isis has over 30 drugs in development.
Speaking about some of those new drugs on "Mad Money", Isis CEO Dr. Stanley Crooke said, "These drugs have the potential to be very effective against some very difficult to treat diseases. We're very excited."
Looking at returns, "Isis Pharma has generated 334 percent gain since I first got behind it nearly two years ago," said Cramer, "And it's up a quick 45 percent since we last spoke to the CEO in late May, but the stock is still more than 20 points off its highs. I think it could have more room to run because this company is a potential game-changer, not to mention a possible takeover target for any growth starved big pharma player looking to expand its pipeline," Cramer said.
Read more from Mad Money with Jim Cramer
Will Alibaba kill bull or feed it?
Could new drug arrest cancer?
Behind Apple's recent decline
All told, Cramer thinks Isis presents a compelling opportunity. "I've liked this company for ages. I think it's one of the best biotech stories around. This stock is right. I don't know how else to put it."
And in case you're wondering, Cramer asked Dr. Crooke if geopolitical events might compel the company to change its name. "I don't want to capitulate to those terrorists," Crooke replied.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com